Skip to Content

Zolpidem Pregnancy and Breastfeeding Warnings

Zolpidem is also known as: Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist

Zolpidem Pregnancy Warnings

Cases of severe neonatal respiratory depression have been reported when this drug was used at the end of pregnancy, especially when used with other central nervous system (CNS) depressants. Infants born to mothers who took benzodiazepines or benzodiazepine-like agents chronically during the latter stages of pregnancy may be at risk for developing physical dependence and withdrawal symptoms in the postnatal period. Additionally, neonatal flaccidity also has been reported in infants born to mothers who received sedative/hypnotic drugs during pregnancy. Animal studies have revealed no evidence of teratogenicity or fertility impairment, but adverse effects including incomplete fetal skeletal ossification and increased embryo-fetal death have occurred. AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

AU, UK: Safety in pregnancy has not been established; avoid use in pregnancy, especially during the first trimester. US: Use during pregnancy only if the potential benefit outweighs the potential risk to the fetus. AU TGA pregnancy category: B3 US FDA pregnancy category: C Comments: -Advise a female patient of childbearing potential to stop using this drug if she intends to become or suspects that she is pregnant. -Effects on the neonate (e.g., hypothermia, hypotonia, moderate respiratory depression) can be expected if this drug is administered during the late phase of pregnancy or during labor.

See references

Zolpidem Breastfeeding Warnings

Breastmilk collected 3 hours after a single oral 20 mg dose of this drug was administered to 5 nursing mothers (who were 3 to 4 days postpartum) showed the breastmilk contained between 0.004% to 0.019% of the maternal dosage; the drug was undetectable (less than 0.5 mcg/L) in the breastmilk 13 and 16 hours after the dose. In animals, administration of this drug during the latter part of pregnancy and throughout lactation produced decreased offspring growth and survival at all but the lowest dose tested.

AU, UK: Use in nursing mothers is not recommended. US: Use with caution in nursing mothers. Excreted into human milk: Yes Comments: Due to the low levels of this drug in breastmilk and its short half-life, amounts ingested by nursing infants are small and would not be expected to cause any adverse effects in these infants.

See references

References for pregnancy information

  1. "Product Information. Ambien CR (zolpidem)." Sanofi-Synthelabo Inc, New York, NY.
  2. "Product Information. Intermezzo (zolpidem)." Purdue Pharma LP, Stamford, CT.
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  5. "Product Information. Zolpimist (zolpidem)." Magna Pharmaceuticals Inc, Louisville, KY.
  6. "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.
  7. "Product Information. Edluar (zolpidem)." Meda Pharmaceuticals, Somerset, NJ.

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  4. "Product Information. Zolpimist (zolpidem)." Magna Pharmaceuticals Inc, Louisville, KY.
  5. "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.
  6. "Product Information. Edluar (zolpidem)." Meda Pharmaceuticals, Somerset, NJ.
  7. "Product Information. Intermezzo (zolpidem)." Purdue Pharma LP, Stamford, CT.
  8. "Product Information. Ambien CR (zolpidem)." Sanofi-Synthelabo Inc, New York, NY.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide